Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Oral Disintegrating Tablets of Proton Pump Inhibitors for Chronic Gastroesophageal Reflux Disease: An Update

Author(s): Avani Gupta, Juber Akhtar*, KC Rastogi, Badruddeen, Mohammad Irfan Khan and Mohammad Ahmad

Volume 15, Issue 3, 2023

Published on: 13 March, 2023

Page: [199 - 206] Pages: 8

DOI: 10.2174/2589977515666230221160449

Price: $65

Abstract

Oral disintegrating tablets (ODT) offer an attractive choice for Gastroesophageal Reflux Disease (GERD) patients suffering from dysphagia. In chronic condition, GERD patient suffers from severe erosive esophagitis. Thus patients feel difficulty and pain during swallowing, which results in patient in-compliance toward medication of tablets or capsules- especially in geriatrics and pediatric patients. These symptoms of GERD patients have attracted the formulation scientists in improving the formulation methodology for such patients. Orally disintegrating tablets could increase the therapeutic impact and drug compliance in these patients. The aim of this compilation is to provide a more convenient way to develop an oral disintegrating drug delivery system of proton pump inhibitors in patients suffering from odynophagia, associated with chronic Gastroesophageal Reflux Disease (GERD). Oral disintegrating tablets (ODT), when placed on the tongue, can quickly disintegrate and release the medicament. It later dissolves or disperses in saliva without any additional water. The saliva containing drug can easily be swallowed and descends into the stomach leading to maximum absorption from the mouth, throat, and upper esophagus. The patient compliance and bio-availability of Oral disintegrating tablets (ODT) are high compared to other conventional tablets.

Next »
Graphical Abstract

[1]
Yen HH, Yang CW, Su WW, Soon MS, Wu SS, Lin HJ. Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012; 12(1): 66.
[http://dx.doi.org/10.1186/1471-230X-12-66] [PMID: 22681960]
[2]
Wiedey R, Kokott M, Breitkreutz J. Orodispersible tablets for pediatric drug delivery: current challenges and recent advances. Expert Opin Drug Deliv 2021; 18(12): 1873-90.
[http://dx.doi.org/10.1080/17425247.2021.2011856] [PMID: 34822316]
[3]
Oda K, Iwakiri R, Hara M, et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig Dis Sci 2005; 50(10): 1921-6.
[http://dx.doi.org/10.1007/s10620-005-2962-5] [PMID: 16187198]
[4]
Jacob P, Kahrilas PJ, Vanagunas A. Peristaltic dysfunction associated with nonobstructive dysphagia in reflux disease. Dig Dis Sci 1990; 35(8): 939-42.
[http://dx.doi.org/10.1007/BF01537240] [PMID: 2384039]
[5]
Johnston N, Dettmar PW, Strugala V, Allen JE, Chan WW. Laryngopharyngeal reflux and GERD. Ann N Y Acad Sci 2013; 1300(1): 71-9.
[http://dx.doi.org/10.1111/nyas.12237] [PMID: 24117635]
[6]
Chen J, Brady P. Gastroesophageal reflux disease. Gastroenterol Nurs 2019; 42(1): 20-8.
[http://dx.doi.org/10.1097/SGA.0000000000000359] [PMID: 30688703]
[7]
Hägg M, Tibbling L, Franzén T. Esophageal dysphagia and reflux symptoms before and after oral IQoro R training. World J Gastroenterol 2015; 21(24): 7558-62.
[http://dx.doi.org/10.3748/wjg.v21.i24.7558] [PMID: 26140003]
[8]
Young A, Kumar MA, Thota PN. GERD: A practical approach. Cleve Clin J Med 2020; 87(4): 223-30.
[http://dx.doi.org/10.3949/ccjm.87a.19114] [PMID: 32238378]
[9]
U.S. food and drug administration.. Guidance for industry: Size, shape and other physical attributes of generic tablets and capsules. Silver Spring, MD, USA 2015.
[10]
Okuda Y, Irisawa Y, Okimoto K, Osawa T, Yamashita S. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int J Pharm 2009; 382(1-2): 80-7.
[http://dx.doi.org/10.1016/j.ijpharm.2009.08.010] [PMID: 19686825]
[11]
de Argila CM, Ponce J, Márquez E, et al. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study. Clin Drug Investig 2007; 27(11): 765-70.
[http://dx.doi.org/10.2165/00044011-200727110-00003] [PMID: 17914895]
[12]
Agiba AM, Abdel-Hamid S, Nasr M, Geneidi AS. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and physicomechanical characterization. Curr Drug Deliv 2018; 15(2): 267-77.
[http://dx.doi.org/10.2174/1567201814666170320143824] [PMID: 28322163]
[13]
Chinwala M. Recent formulation advances and therapeutic usefulness of Orally Disintegrating Tablets (ODTs). Pharmacy (Basel) 2020; 8(4): 186.
[http://dx.doi.org/10.3390/pharmacy8040186] [PMID: 33050437]
[14]
Kakutani R, Muro H, Makino T. Development of a new disintegration method for orally disintegrating tablets. Chem Pharm Bull (Tokyo) 2010; 58(7): 885-90.
[http://dx.doi.org/10.1248/cpb.58.885] [PMID: 20606331]
[15]
Freston JW, Chiu YL, Mulford DJ, Ballard ED II. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17(3): 361-7.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01455.x] [PMID: 12562448]
[16]
Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 2004; 21(6): 433-76.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i6.10] [PMID: 15658933]
[17]
Yadlapati R, DeLay K. Proton Pump Inhibitor–Refractory Gastroesophageal Reflux Disease. Med Clin North Am 2019; 103(1): 15-27.
[http://dx.doi.org/10.1016/j.mcna.2018.08.002] [PMID: 30466671]
[18]
Walle KV, Funk LM, Xu Y, et al. Persistent Dysphagia Rate After Antireflux Surgery is Similar for Nissen Fundoplication and Partial Fundoplication. J Surg Res 2019; 235: 52-7.
[http://dx.doi.org/10.1016/j.jss.2018.09.036] [PMID: 30691837]
[19]
Wang KK, Gener JR. Gastroesophageal reflux disease (GERD). In: Kuipers EJ, Ed. Encyclopedia of gastroenterology. (2nd ed.). Oxford: Academic Press 2020; pp. 672-81.
[20]
Barnhart DC. Gastroesophageal reflux disease in children. Semin Pediatr Surg 2016; 25(4): 212-8.
[http://dx.doi.org/10.1053/j.sempedsurg.2016.05.009] [PMID: 27521711]
[21]
Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease. JAMA 2020; 324(24): 2565.
[http://dx.doi.org/10.1001/jama.2020.21573] [PMID: 33351044]
[22]
Brunton LL, Goodman LS, Blumenthal D, Buxton I. Goodman and Gilman’s manual of pharmacology and therapeutics. McGraw-Hill 2007.
[23]
McCarty EB, Chao TN. Dysphagia and Swallowing Disorders. Med Clin North Am 2021; 105(5): 939-54.
[http://dx.doi.org/10.1016/j.mcna.2021.05.013] [PMID: 34391544]
[24]
Dey N, Rao SMM. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res 2008; 7: 1067-75.
[25]
Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. The continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9(4): 363-78.
[http://dx.doi.org/10.1111/j.1365-2036.1995.tb00394.x] [PMID: 8527612]
[26]
Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. Gut Liver 2018; 12(1): 7-16.
[http://dx.doi.org/10.5009/gnl16615] [PMID: 28427116]
[27]
Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag 2007; 3(2): 231-43.
[http://dx.doi.org/10.2147/tcrm.2007.3.2.231] [PMID: 18360632]
[28]
Bernshteyn MA, Masood U. Pantoprazole. StatPearls. Treasure island, FL: StatPearls Publishing 2022.
[29]
Calabrese C, Fabbri A, Febo GD. Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging 2007; 2(1): 85-92.
[http://dx.doi.org/10.2147/ciia.2007.2.1.85] [PMID: 18044079]
[30]
Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash) 2000; 40(1): 52-62.
[31]
Anonymous . Gastric Acid-Related Diseases and PPIs, Therapeutic trends, canadian pharmaceutical marketing. Canada: IMS Health Canada 2010; pp. 37-40.
[32]
Çelebi A, Aydin D, Kocaman O, Konduk BT, Şentürk O, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2020; 27(5): 408-14.
[http://dx.doi.org/10.5152/tjg.2016.15514] [PMID: 27782887]
[33]
Schnoll-Sussman F, Niec R, Katz PO. Proton Pump Inhibitors. Gastrointest Endosc Clin N Am 2020; 30(2): 239-51.
[http://dx.doi.org/10.1016/j.giec.2019.12.005] [PMID: 32146944]
[34]
Avner DL. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther 2000; 22(10): 1169-85.
[http://dx.doi.org/10.1016/S0149-2918(00)83061-1] [PMID: 11110229]
[35]
Garner A, Fadlallah H. Pantoprazole: a new and more specific proton pump inhibitor. Expert Opin Investig Drugs 1997; 6(7): 885-93.
[http://dx.doi.org/10.1517/13543784.6.7.885] [PMID: 15989651]
[36]
Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol 2000; 95(11): 3071-80.
[http://dx.doi.org/10.1111/j.1572-0241.2000.03254.x] [PMID: 11095320]
[37]
Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67(1-2): 1-5.
[http://dx.doi.org/10.1159/000070393] [PMID: 12743433]
[38]
Kadam VD, Gattani SG. Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Deliv 2010; 17(5): 343-51.
[http://dx.doi.org/10.3109/10717541003762821] [PMID: 20429842]
[39]
Sharma S, Singh K. Oral disintegrating tablets – An updated patent perspective. Recent Pat Drug Deliv Formul 2021; 14(3): 166-90.
[http://dx.doi.org/10.2174/1872211314999201123202930] [PMID: 33231150]
[40]
Ghourichay MP, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and quality control of orally disintegrating tablets (ODTs): Recent advances and perspectives. BioMed Res Int 2021; 2021: 6618934.
[http://dx.doi.org/10.1155/2021/6618934] [PMID: 34977245]
[41]
U.S. food and drug administration. Guidance for industry: Orally disintegrating tablets. Silver Spring, MD, USA 2008.
[42]
Pabari RM, Ramtoola Z. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets. Int J Pharm 2012; 430(1-2): 18-25.
[http://dx.doi.org/10.1016/j.ijpharm.2012.03.021] [PMID: 22465631]
[43]
Al-khattawi A, Mohammed AR. Challenges and emerging solutions in the development of compressed orally disintegrating tablets. Expert Opin Drug Discov 2014; 9(10): 1109-20.
[http://dx.doi.org/10.1517/17460441.2014.941802] [PMID: 25045997]
[44]
Hoon YT, Yourong F, Kinam P. Material properties for making fast dissolving tablets by a compression method. J Mater Chem 2008; 18(8): 3527-35.
[45]
Xu Y, Yan G, Wen X, et al. Preparation, evaluation, and pharmacokinetics in beagle dogs of a taste-masked flunixin meglumine orally disintegrating tablet prepared using hot-melt extrusion technology and D-optimal mixture design. Eur J Pharm Sci 2022; 168: 106019.
[http://dx.doi.org/10.1016/j.ejps.2021.106019] [PMID: 34563655]
[46]
Cantor SL, Khan MA, Gupta A. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydro-chloride. Drug Dev Ind Pharm 2015; 41(7): 1156-64.
[http://dx.doi.org/10.3109/03639045.2014.935392] [PMID: 25000481]
[47]
McLaughlin SB. Orally disintegrating tablets- effect of recent FDA guidance on ODT technologies and application. Pharmaceut Technol 2009. Available from: https://www.scienceopen.com/document?vid=b58529df-32df-4725-97a4-d5b5d7784bea
[48]
Nakamura S, Fukai T, Sakamoto T. Orally disintegrating tablet manufacture via direct powder compression using cellulose nanofiber as a functional additive. AAPS PharmSciTech 2022; 23(1): 37.
[http://dx.doi.org/10.1208/s12249-021-02194-5] [PMID: 34950985]
[49]
Agrawal S, Fernandes J, Shaikh F, Patel V. Quality aspects in the development of pelletized dosage forms. Heliyon 2022; 8(2): e08956.
[http://dx.doi.org/10.1016/j.heliyon.2022.e08956] [PMID: 35243077]
[50]
Salve V, Mishra R, Nandgude T. Development and optimization of a floating multiparticulate drug delivery system for norfloxacin. Turkish. J Pharmaceut Sci 2019; 16(3): 326-34.
[http://dx.doi.org/10.4274/tjps.galenos.2018.99266] [PMID: 32454731]
[51]
Asghar LF, Chandran S. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharm Sci 2006; 9(3): 327-38.
[PMID: 17207416]
[52]
Maderuelo C, Lanao JM, Zarzuelo A. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. Eur J Pharm Sci 2019; 138: 105019.
[http://dx.doi.org/10.1016/j.ejps.2019.105019] [PMID: 31374253]
[53]
Ali J, Rahman MA. Development and in vitro evaluation of enteric coated multiparticulate system for resistant tuberculosis. Indian J Pharm Sci 2008; 70(4): 477-81.
[http://dx.doi.org/10.4103/0250-474X.44597] [PMID: 20046774]
[54]
AlHusban FA, El-Shaer AM, Jones RJ, Mohammed AR. Recent patents and trends in orally disintegrating tablets. Recent Pat Drug Deliv Formul 2010; 4(3): 178-97.
[http://dx.doi.org/10.2174/187221110793237574] [PMID: 20626334]
[55]
Beckert TE, Lehmann K, Schmidt PC. Compression of enteric-coated pellets to disintegrating tablets. Int J Pharm 1996; 143(1): 13-23.
[http://dx.doi.org/10.1016/S0378-5173(96)04631-5]
[56]
Al-khattawi A, Mohammed AR. Compressed orally disintegrating tablets: excipients evolution and formulation strategies. Expert Opin Drug Deliv 2013; 10(5): 651-63.
[http://dx.doi.org/10.1517/17425247.2013.769955] [PMID: 23387409]
[57]
Bodmeier R. Tableting of coated pellets. Eur J Pharm Biopharm 1997; 43(1): 1-8.
[http://dx.doi.org/10.1016/S0939-6411(96)00028-8]
[58]
Breitkreutz J, Boos J. Drug delivery and formulations. Handb Exp Pharmacol 2011; 205: 91-107.
[http://dx.doi.org/10.1007/978-3-642-20195-0_4] [PMID: 21882107]
[59]
Garg Y, Pathak K. Design and in vitro performance evaluation of purified microparticles of pravastatin sodium for intestinal delivery. AAPS PharmSciTech 2011; 12(2): 673-82.
[http://dx.doi.org/10.1208/s12249-011-9626-x] [PMID: 21594729]
[60]
Debunne A, Vervaet C, Remon JP. Development and in vitro evaluation of an enteric-coated multiparticulate drug delivery system for the administration of piroxicam to dogs. Eur J Pharm Biopharm 2002; 54(3): 343-8.
[http://dx.doi.org/10.1016/S0939-6411(02)00117-0] [PMID: 12445566]
[61]
Combessis D, Corvaisier D, Gil A, Guerin E. Pharmaceutical formulation and process for its preparation. US Patent no. 20060018964, 2006.
[62]
Chansanroj K. Enteric coating of pharmaceutical products Glatt International Times. 2010. Available from: https://www.yumpu.com/en/document/view/5443535/no-30-glatt
[63]
Felton LA, Haase MM, Shah NH, et al. Physical and enteric properties of soft gelatin capsules coated with eudragit® L 30 D-55. Int J Pharm 1995; 113(1): 17-24.
[http://dx.doi.org/10.1016/0378-5173(94)00169-6]
[64]
Szczepanska M, Paduszynski P, Kotlowska H, Sznitowska M. Optimization of the coating process of minitablets in two different lab-scale fluid bed systems. Drug Dev Ind Pharm 2020; 46(1): 31-41.
[http://dx.doi.org/10.1080/03639045.2019.1698596] [PMID: 31773983]
[65]
Shimizu T, Nakano Y, Morimoto S, Tabata T, Hamaguchi N, Igari Y. Formulation study for lansoprazole fast-disintegrating tablet. I. Effect of compression on dissolution behavior. Chem Pharm Bull (Tokyo) 2003; 51(8): 942-7.
[http://dx.doi.org/10.1248/cpb.51.942] [PMID: 12913232]
[66]
Aguilar-Díaz JE, García-Montoya E, Pérez-Lozano P, Suñe-Negre JM, Miñarro M, Ticó JR. The use of the SeDeM Diagram expert system to determine the suitability of diluents–disintegrants for direct compression and their use in formulation of ODT. Eur J Pharm Biopharm 2009; 73(3): 414-23.
[http://dx.doi.org/10.1016/j.ejpb.2009.07.001] [PMID: 19602435]
[67]
AlHusban F, Perrie Y, Mohammed AR. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. Eur J Pharm Biopharm 2011; 79(3): 627-34.
[http://dx.doi.org/10.1016/j.ejpb.2011.05.014] [PMID: 21693189]
[68]
Sohail Arshad M, Zafar S, Yousef B, et al. A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing. Adv Drug Deliv Rev 2021; 178: 113840.
[http://dx.doi.org/10.1016/j.addr.2021.113840] [PMID: 34147533]
[69]
John P, Bergstrand A, Lövgren KI. Multiple unit pharmaceutical preparation containing proton pump inhibitor Patent no. CN-1134668-A, 2004.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy